Prostate cancer is the most common male cancer
Millions of men must make a difficult binary choice today:
Do something aggressive early on — or surveil for years.
Alessa can offer both: therapeutic surveillance.
Thirteen percent of men will be diagnosed with prostate cancer in their lifetimes
An estimated 1.5 million men are diagnosed with prostate cancer each year worldwide
Seventy six percent of men with prostate cancer have localized disease
Sources: NCI SEER Database, Schafer et al. 2025, Eur Urol; American Cancer Society
Localized Prostate Cancer Explained
About 76% of prostate cancers are diagnosed while still confined to the prostate. Each year, ~240,000 men in the U.S. and over one million worldwide are diagnosed with localized prostate cancer.
Despite the high prevalence, treatment options remain fraught with difficult choices: active surveillance (regular exams and repeat biopsies) leaves patients anxious and vulnerable to the risk of progression, while whole gland treatment (radical prostatectomy or radiation therapy) often causes considerable short and long-term side effects, including incontinence or impotence.
Alessa’s Focus: Therapeutic Surveillance
There is an immediate need for a therapy that has fewer side effects for those men who worry about progression and are not well served with active surveillance.
